

# **Improved *Helicobacter pylori* Eradication Rate of Tailored Triple Therapy by Adding *Lactobacillus delbrueckii* and *Streptococcus thermophilus* in Northeast Region of Thailand: A Prospective Randomized Controlled Clinical Trial**

[Taweesak Tongtawee](#)<sup>1</sup>, [Chavaboon Dechsukhum](#)<sup>2</sup>, [Wilairat Leeanansaksiri](#)<sup>3</sup>, [Soraya Kaewpitoon](#)<sup>4</sup>, [Natthawut Kaewpitoon](#)<sup>5</sup>, [Ryan A Loyd](#)<sup>4</sup>, [Likit Matrakool](#)<sup>1</sup>, [Sukij Panpimanmas](#)<sup>1</sup>

Affiliations


- PMID: [26167176](#)
- PMCID: [PMC4475728](#)
- DOI: [10.1155/2015/518018](#)

Free PMC article

## **Abstract**


Background and Aim. To evaluate the effect of *Lactobacillus delbrueckii* subsp. *bulgaricus* and *Streptococcus thermophilus* to *Helicobacter pylori* eradication in different periods of therapeutic protocol. Methods. Infected patients were randomized to one-week tailored triple therapy (esomeprazole 20 mg bid, clarithromycin 500 mg bid/metronidazole 400 mg tid if clarithromycin resistant, and amoxicillin 1000 mg bid) with placebo (group 1, n=100); one week of pretreatment with probiotics (group 2, n=100); and one week of pretreatment with probiotic followed by one week of the same probiotics after treatment (group 3, n=100). Result. PP analysis involved 292 patients, 98 in group 1, 97 in group 2, and 97 in group 3. Successful eradication was observed in 229 patients; by PP analysis, the eradication rates were significantly higher ( $P<0.01$ , 95% CI; 0.71-0.97) in group 2 and group 3 than group 1. ITT analysis eradication rates were significantly higher in group 2 and group 3 than group 1 ( $P<0.01$  95% CI; 0.72-0.87), and there is no significant difference between the three groups ( $P=0.32$ ) in terms of adverse events. Conclusion. Adding probiotics before or before and after tailored treatment can improve *Helicobacter pylori* eradication rates. This trial is registered with Thai Clinical Trials Registry number: TCTR20141209001.

## **Figures**




**Figure 1**

Flowchart of the study. Probiotic:...




**Figure 2**

Flow diagram showing numbers of...



**Figure 3**

Pattern of clarithromycin resistance from...



**Figure 4**

*Helicobacter pylori* eradication rate (ITT:...)

## Similar articles

- [Effect of Pretreatment with Lactobacillus delbrueckii and Streptococcus thermophilus on Tailored Triple Therapy for Helicobacter pylori Eradication: A Prospective Randomized Controlled Clinical Trial.](#)

Tongtawee T, Dechsukhum C, Leeanansaksiri W, Kaewpitoon S, Kaewpitoon N, Loyd RA, Matrakool L, Panpimanmas S. Asian Pac J Cancer Prev. 2015;16(12):4885-90. doi: 10.7314/apjcp.2015.16.12.4885. PMID: 26163609 Clinical Trial.

- [Adjuvant probiotics improve the eradication effect of triple therapy for Helicobacter pylori infection.](#)

Du YQ, Su T, Fan JG, Lu YX, Zheng P, Li XH, Guo CY, Xu P, Gong YF, Li ZS. World J Gastroenterol. 2012 Nov 21;18(43):6302-7. doi: 10.3748/wjg.v18.i43.6302. PMID: 23180952 Free PMC article. Clinical Trial.

- [Efficacy and tolerability of first-line triple therapy with levofloxacin and amoxicillin plus esomeprazole or rabeprazole for the eradication of Helicobacter pylori infection and the effect of CYP2C19 genotype: a 1-week, randomized, open-label study in Chinese adults.](#)

Pan X, Li Y, Qiu Y, Tang Q, Qian B, Yao L, Shi R, Zhang G. Clin Ther. 2010 Nov;32(12):2003-11. doi: 10.1016/j.clinthera.2010.11.005. PMID: 21118735 Clinical Trial.

- [Efficacy of Probiotic Supplementation Therapy for Helicobacter pylori Eradication: A Meta-Analysis of Randomized Controlled Trials.](#)

Lü M, Yu S, Deng J, Yan Q, Yang C, Xia G, Zhou X. PLoS One. 2016 Oct 10;11(10):e0163743. doi: 10.1371/journal.pone.0163743. eCollection 2016. PMID: 27723762 Free PMC article. Review.

- [Efficacy and safety of probiotic-supplemented triple therapy for eradication of Helicobacter pylori in children: a systematic review and network meta-analysis.](#)

Feng JR, Wang F, Qiu X, McFarland LV, Chen PF, Zhou R, Liu J, Zhao Q, Li J. Eur J Clin Pharmacol. 2017 Oct;73(10):1199-1208. doi: 10.1007/s00228-017-2291-6. Epub 2017 Jul 5. PMID: 28681177 Review.

See all similar articles

## Cited by 3 articles

- [Efficacy and safety of probiotics in eradicating Helicobacter pylori: A network meta-analysis.](#)

Shi X, Zhang J, Mo L, Shi J, Qin M, Huang X. Medicine (Baltimore). 2019 Apr;98(15):e15180. doi: 10.1097/MD.00000000000015180. PMID: 30985706 Free PMC article.

- [Potential role of probiotics in the management of gastric ulcer.](#)

Khoder G, Al-Menhali AA, Al-Yassir F, Karam SM. Exp Ther Med. 2016 Jul;12(1):3-17. doi: 10.3892/etm.2016.3293. Epub 2016 Apr 26. PMID: 27347010 Free PMC article.

- [Characteristics and Risk Factors of Helicobacter pylori Associated Gastritis: A Prospective Cross-Sectional Study in Northeast Thailand.](#)

Tongtawee T, Kaewpitoon S, Kaewpitoon N, Dechsukhum C, Leeansaksiri W, Loyd RA, Matrakool L, Panpimanmas S. Gastroenterol Res Pract.

2016;2016:9130602. doi: 10.1155/2016/9130602. Epub 2016 Mar 2. PMID: 27042174 Free PMC article.

## References

1.
  1. Suerbaum S., Michetti P. Helicobacter pylori infection. *The New England Journal of Medicine*. 2002;347(15):1175–1186. doi: 10.1056/nejmra020542. - [DOI](#) - [PubMed](#)
2.
  1. Asaka M., Kato M., Sugiyama T., et al. Follow-up survey of a large-scale multicenter, double-blind study of triple therapy with lansoprazole, amoxicillin, and clarithromycin for eradication of Helicobacter pylori in Japanese peptic ulcer patients. *Journal of Gastroenterology*. 2003;38(4):339–347. doi: 10.1007/s005350300061. - [DOI](#) - [PubMed](#)
3.
  1. Kim N., Kim J. M., Kim C. H., et al. Institutional difference of antibiotic resistance of Helicobacter pylori strains in Korea. *Journal of Clinical Gastroenterology*. 2006;40(8):683–687. doi: 10.1097/00004836-200609000-00004. - [DOI](#) - [PubMed](#)
4.
  1. Jung M. K., Joo S. K., Hyun C. J., Kim N., Kim Y.-J., In S. S. Distribution of antibiotic MICs for Helicobacter pylori strains over a 16-year period in patients from Seoul, South Korea. *Antimicrobial Agents and Chemotherapy*. 2004;48(12):4843–4847. doi: 10.1128/aac.48.12.4843-4847.2004. - [DOI](#) - [PMC](#) - [PubMed](#)
5.
  1. Vilaichone R.-K., Gumnarai P., Ratanachu-ek T., Mahachai V. Nationwide survey of Helicobacter pylori antibiotic resistance in Thailand. *Diagnostic Microbiology and Infectious Disease*. 2013;77(4):346–349. doi: 10.1016/j.diagmicrobio.2013.08.010. - [DOI](#) - [PubMed](#)

## Related information

- [MedGen](#)

## LinkOut - more resources

- **Full Text Sources**
  - [Europe PubMed Central](#)
  - [Hindawi Limited](#)
  - [PubMed Central](#)
- **Other Literature Sources**

- [scite Smart Citations](#)
- **Miscellaneous**
  - [NCI CPTAC Assay Portal](#)